Autologous Glypican-3–Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102
- DOI
- 10.1158/2326-6066.cir-25-0855
- Published
- 2026-09-08
- Container
- Cancer Immunology Research
- Publisher
- American Association for Cancer Research (AACR)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1158/2326-6066.cir-25-0855,
title = {Autologous Glypican-3–Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102},
author = {Yasutoshi Kuboki and Takafumi Koyama and Masafumi Ikeda and Tomoyuki Satake and Takeshi Sawada and Yutaka Shimazu and Shunsuke Kondo and Yuki Katsuya and Hideaki Kagehara and Takenori Akaike and Aman Singh and Kondala Atkuri and Petar Pop-Damkov and Koji Tamada and Takako Eguchi. Nakajima},
year = {2026},
journal = {Cancer Immunology Research},
doi = {10.1158/2326-6066.cir-25-0855},
url = {https://doi.org/10.1158/2326-6066.cir-25-0855}
}RIS
TY - JOUR TI - Autologous Glypican-3–Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102 AU - Yasutoshi Kuboki AU - Takafumi Koyama AU - Masafumi Ikeda AU - Tomoyuki Satake AU - Takeshi Sawada AU - Yutaka Shimazu AU - Shunsuke Kondo AU - Yuki Katsuya AU - Hideaki Kagehara AU - Takenori Akaike AU - Aman Singh AU - Kondala Atkuri AU - Petar Pop-Damkov AU - Koji Tamada AU - Takako Eguchi. Nakajima PY - 2026 JO - Cancer Immunology Research DO - 10.1158/2326-6066.cir-25-0855 UR - https://doi.org/10.1158/2326-6066.cir-25-0855 ER -
APA
Kuboki, Y., Koyama, T., Ikeda, M., Satake, T., Sawada, T., Shimazu, Y., Kondo, S., Katsuya, Y., Kagehara, H., Akaike, T., Singh, A., Atkuri, K., Pop-Damkov, P., Tamada, K., & Nakajima, T. E. (2026). Autologous Glypican-3–Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-25-0855
Source records
- crossref · retrieved 2026-09-26T13:01:04.866Z